134 related articles for article (PubMed ID: 11956278)
1. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Schwartz GK; O'Reilly E; Ilson D; Saltz L; Sharma S; Tong W; Maslak P; Stoltz M; Eden L; Perkins P; Endres S; Barazzoul J; Spriggs D; Kelsen D
J Clin Oncol; 2002 Apr; 20(8):2157-70. PubMed ID: 11956278
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
4. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Shah MA; Kortmansky J; Motwani M; Drobnjak M; Gonen M; Yi S; Weyerbacher A; Cordon-Cardo C; Lefkowitz R; Brenner B; O'Reilly E; Saltz L; Tong W; Kelsen DP; Schwartz GK
Clin Cancer Res; 2005 May; 11(10):3836-45. PubMed ID: 15897584
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.
George S; Kasimis BS; Cogswell J; Schwarzenberger P; Shapiro GI; Fidias P; Bukowski RM
Clin Lung Cancer; 2008 May; 9(3):160-5. PubMed ID: 18621626
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.
Luke JJ; D'Adamo DR; Dickson MA; Keohan ML; Carvajal RD; Maki RG; de Stanchina E; Musi E; Singer S; Schwartz GK
Clin Cancer Res; 2012 May; 18(9):2638-47. PubMed ID: 22374332
[TBL] [Abstract][Full Text] [Related]
7. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Rathkopf D; Dickson MA; Feldman DR; Carvajal RD; Shah MA; Wu N; Lefkowitz R; Gonen M; Cane LM; Dials HJ; Winkelmann JL; Bosl GJ; Schwartz GK
Clin Cancer Res; 2009 Dec; 15(23):7405-11. PubMed ID: 19934304
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Dickson MA; Shah MA; Rathkopf D; Tse A; Carvajal RD; Wu N; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1113-21. PubMed ID: 20953860
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Rudek MA; Bauer KS; Lush RM; Stinson SF; Senderowicz AM; Headlee DJ; Arbuck SG; Cox MC; Murgo AJ; Sausville EA; Figg WD
Ann Pharmacother; 2003 Oct; 37(10):1369-74. PubMed ID: 14519054
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Fornier MN; Rathkopf D; Shah M; Patil S; O'Reilly E; Tse AN; Hudis C; Lefkowitz R; Kelsen DP; Schwartz GK
Clin Cancer Res; 2007 Oct; 13(19):5841-6. PubMed ID: 17908977
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
Zhai S; Senderowicz AM; Sausville EA; Figg WD
Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
